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Effects of terbutaline on the fetal lamb during maternal oxytocin- 9 (1981) Terbutaline, a resorcinol derivative of isoprenaline, is primarily an adrenergic j3 2 -receptor agonist [25] . Terbutaline has been demonstrated äs being a potent inhibitor of myometrial contractlity in vitro [1] . Recent clinical trialshave confirmed the agent's tocolytic activity in both spontaneous and oxytocin-stimulated labor [2, 3, 15] . the investigations showed that terbutaline was well tolerated maternally despite a moderate tachycardia. Antepartum fetal heart rate monitoring and APGAR scores did not demonstrate any unusual or adverse effects on the fetus in human [2, 3, 15] or animal [6, 7] studies. However, presently there are no systematic clinical or other investigations showing the effect of varying matemal doses on the fetus and on uteroplacental circulation. This study was undertaken to investigate doserelated effects of terbutaline on immature fetal lambs. The drug was infused into the maternal circulation in one phase and directly into the fetal circulation in another during oxytocin-induced labor. The fetal cardiovascular and acid-bäse Status was monitored continuously.
l Materials and methods
Ten pregnant ewes and their fetuses (including two sets of twins) were prepared under spinal anesthesia äs described previously [7] . Catheters were introduced into the fetal carotid artery and jugular vein and into the amniotic cavity at hysterotomy. The femoral artery and vein and main maternal uterine vein were also catheterized. An electromagnetic flow probe (Micron Instruments, Calif.) was placed around the uterine artery supplying the pregnant hörn. A minimum period of three days was allowed 0300-5 577/81 /0009-0014$02.00 ©by Walter de Gruyter & Co. -Berlin · New York for postoperative recovery. Twenty-seven investigations making up this study were carried out from 3 to 14 days after surgery (125 to 143 days gestation). At least 24 hours were allowed to elapse between successive investigations of the same animal to ensure recovery of mother and fetus before the next one. Terbutaline (Bricanyl®, Astra Pharmaceutical Products, Inc., Framingham, Mass.) was administered by continuous intravenous infusion to the ewe on four occasions when uterine contractions were not occurring and on eight occasions when uterine contractions were induced by a continuous infusion of oxytocin into a maternal vein. The amount of oxytocin required to induce regul r uterine contractions like those of spontaneous labor in sheep ranged between 20-40 milliunits per minute. In sheep, uterine contractions during the first stage of labour occur 10-20 times each ten minutes with an intensity of at least 10 torr [26] . The oxytocin infusion was maintained throughout the study. After 20 minutes of well-established uterine contractions, terbutaline was infiised into the matemal femoral vein at three sequential rates for 20 minutes each; at 0.2 Mg/kg/min (rate I); at 0.4 μg/kg/min (rate II); and at 0.8 μg/kg/min (rate III). When oxytocin infusion was not administered there were no uterine contractions; the ewes received no drugs other than terbutaline at the established sequential rates. A bolus injection of 250 Mg of terbutaline was given in eight separate investigations, four with oxytocin-induced contractions and the last four without. In seven investigations terbutaline was infiised directly into the fetal jugular vein at a rate of 0.4-10 ^g/kg/min for 20 minutes to examine fetal cardiovascular and acid-base responses. Fetal weight at the time of infusion was estimated according to gestational age [14, 19] , and the fetus was sacrified within 3 days of the final phase of the study. Maternal and fetal blood pressures, heart rates, andintraamniotic pressure were monitored throughout the study and were recorded on a multichannel polygraph. Uterine activity was expressed in Montevideo Units (MVU).Arterialbloodsamples were withdrawn at intervals from the ewe and fetus simultaneously to measure pH, P0 2 and PC0 2 , using Radiometer microelectrodes. Base deficit was calculated according to the SIGGAARD-ANDERSEN nomogram. All results were analyzed by the Student "t" test and, when P values were less than 0.05, were considered statistically significant. Correlations were estimated by linear regression curves.
Results

Continuous maternal administration of terbutaline
The mean value (± S.E.) for oxytocin-induced uterine activity prior to terbutaline infiisions was 229 ± 17 MVU. Terbutaline given at rate I (0.2 μg/ kg/min) reduced uterine activity to 140 ± 24 MVU (39% of the oxytocin-induced level); at rate II (0.4 Mg/kg/min) to 117 ± 16 MVU (44%) and at rate III (0.8 Mg/kg/min) to 21 ± 16 MVU (9%). Reduction in uterine activity during terbutaline infusion was statistically significant at all dose levels. Decreases in both the intensity and frequency of contractions were responsible. Proportional changes in uterine blood flow during oxytocin and terbutaline infusions are illustrated in Fig. 1 . For the eight experiments in which uterine activity was induced with oxytocin, the mean uterine blood flow had been reduced significantly (P < 0.05) to 75% of the pre-oxytocin value prior to terbutaline (baseline), Followtocin value prior to terbutaline (baseline). Following infusion of the drug, uterine blood flow tended to increase above the baseline value, although the change was not significant. In the four experiments in which terbutaline alone was administered to the ewe, blood flow remained essentially unchanged at rates I and II, but feil to 76% of control with rate III. However, because the number of experiments was small, this change was not found to be statistically significant. Maternal mean blood pressure showed no significant change during infusion of oxytocin and terbutaline alone (Fig. 1) . The control value for mean arterial blood pressure was 86 ± 3 torr and remained essentially unaltered throughout the study with systolic blood pressure of 115 ± 2.6 torr for the control period, 121 ± 2 torr after oxytocin infusion and 128 ± 7.5 torr at the end of terbutaline administration. The corresponding values for diastolic blood pressure were 71 ± 5.1, 72 ± 4.2 and 65 ± 3.8 torr respectively. The heart rate prior to oxytocin infusion was 91 ± 2.4 beats/ min. With oxytocin infusion the rate rose to 102 ±4.2 beats/min. Following terbutaline infusion heart rate increased, reaching a maximum of 158 ± 11 beats/min (P < 0.01) with rate III. The chronotropic effect of terbutaline, the increase in heart rate during the infusion, was simflar in the animals not given oxytocin (Fig. 1) . Changes in arterial blood pressure and heart rate of the fetus before and at the end of continuous matemal infusion of terbutaline are seen in Tab. L When oxytocin with terbutaline or terbutaline alone was administered to the a ewes, the fetuses showed no signiftcant alteration of either blood pressure or heart rate. Mean maternal pHa duiing the control period was 7.47 ± 0.006;Pa0 2 , 91 ± 3.7 torr;PaCO 2 , 33 ± 1.9 torr, and base deficit, 0.7 ± 2.0 mEq/1. These values were maintained throughout the study. The pHa and PaO 2 in the fetus during terbutaline infusion are depicted in Fig. 2 . ver-a mean control values for the acid -base state of the fetus prior to the infusion of terbutaline were pHa, 7.38 ±0.017; PaO 2 , 25 ± 1.0 torr; PaCO 2 ,45 + 1.5 torr and base deficit, 1.5 ± 0.8 mEq/L. These values did not change significantly during maternal infusion of combined oxytocin and terbutaline or terbutaline alone. At the end of the highest infusion rate of terbutaline, PaCO 2 was 51 ± 5.6 torr, and base Tab. 1. Changes in fetal arterial blood pressure and heart rate following administration of terbutaline to the ewe. deficit, 1.2 ± 0.68 mEq/L. Mean fetal hematocrit for the control period was 35 ± 2.8%. This did not vary significantly during the course of the study.
Maternal bolus injection of terbutaline
Bolus intravenous injection of 250 μ § of terbutaline to the ewes with well established uterine contractions totally suppressed uterine activity within 30 seconds, and the suppression lasted an average of 9 minutes. Initially, uterine blood flow tended to decrease briefly, followed by a significant increase over the preinfusion value (P < 0.02). A typical recording of uterine blood flow, amniotic pressure, arterial pressure andheart rate of both ewe and fetus is shown in Fig. 3 . In the animals with oxytocin-induced uterine contractions, blood flow remained essentially the same following a bolus injsction of terbutaline s in the absence of sponianeous uterine activity previously (n = 4). Bolus injection had a biphasic effect on maternal blood pressure; a fall in systolic from the control value of 118 ± 2.4 to 110 ± 2 torr (P < 0.05); and a fall in diastolic blood pressure from 98 ± 2.4 to 80 ± 3.1 torr (P < 0.02) in the first 15 seconds. This was followed by a rise in both systolic and diastolic pressures with a significant increase in pulse pressure from 20 ± l to 34 ± 6 torr (P < 0.05).
Maternal heart rate rose from 110 ±2. Fig. 3 . A typical recording of uterine ftlood flow, intra-amniotic pressure, heart rate and arterial pressure of the ewe, and fetal heart rate following a maternal bolus intravenous injection of terbutaline (250 Mg). Uterine contractions had been induced by continuous infusion of oxytocin.
Continuous administration of terbutaline to fetus
In four immature fetuses (gestational ages 125-135 days) blood pressure and heart rate remained essentially unchanged when terbutaline (0.4-0.8 Mg/kg/ min) was infused directly. Heart rate was 165 ± 15 beats/min before the infusion and 164 ± 11 beats/ min afterward. Mean arterial pressure was 51 ± 3 torr before infusion and 50 ± 4 torr after. In these fetuses, the dose necessary to alter the heart rate was 4-10 g/kg/min. In contrast, in three nearterm fetuses (143 days gestation) receiving terbutaline with a rate of 0.4 jug/kg/min, heart rate rose from 157 ± 7 to 210 ± 29 beats/min, but blood pressure remained unchanged: 52 ± 2 torr before and 51 ± l torr after infusion. Fetal acid-base state remained unchanged throughout.
Discussion
This study demonstrated that terbutaline given to the ewe is effective in suppressing oxytocinaugmented uterine contractions without reducing uterine blood flow or causing adverse effects in the fetus, thus confirming earlier clinical trials in man, and investigations in primates and sheep [2, 3, 6, 7, 15] . Terbutaline activity is related to a capacity to stimulate the myometrium 0 2 adrenergic receptors. The most commonly used /3 2 -selective adrenergic agonists, orciprenaline, ritodrine, salbutamol, fenoterol (Th 1165a) äs well äs terbutaline have all been shown to be capable of suppressing labor. The risk of maternal tachycardia, hypotension o r respiratory depressionlimits the use of isoxsuprine and its derivatives, nonspecific j3-adrenergic agonists and other tocölytics (including diazoxide, alcohol, magnesium sulphate [12, 13, 18, 20, 24] . In contrast, this study shows that terbutaline does not have an adverse effect on blood pressure in the pregnant ewe. Tolerance is limited only by a consistent increase in heart rate. This same limitation has been reported'for salbutamol [17] , fenoterol [16] and ritodrine [18] in man. Tachycardia is an even greater problem with orciprenaline, which may induce matemal sinus arrhythmias [16] . In patients treated with terbutaline, maternal heart rates did not exceed 120 beats/min, and troublesome palpitations rarely occurred [2, 15] . Many tocolytic agents may also cause fetal hypotension, tachycardia and acidosis. Terbutaline administration into the maternal sheep circulation in this study, on the contrary, did not härm the fetus. When the drug was infused directly into the fetal circulation, the dose response pattern in the mature fetus (0.4 g/kg/min) was comparable to that of the ewe (0.2-0.8 g/kg/min). This suggests that if terbutaline does cross the sheep placenta, the amount reaching the fetus falls short of the amount required to produce a cardiovascular response. Immature fetuses (125-135 days of gestation) tolerated systemic administration of terbutaline without signs of distress. In these fetuses, the dose required to elicit a change in heart rate was 10-25 times greater (4-10 Mg/kg/ min) than the amount used in the mature fetus or the pregnant ewe to produce a comparable change in heart rate. This suggests an age-related response to terbutaline, perhaps due to the factthatvascular adrenergic j3 2 -receptors are notyetfijlly developed. The increase in heart rate seen in mature fetuses may be in response to peripheral vasodilatation and not to a direct ß v effect on the heart. This, in fact, has been shown in maternal tachycardia, which was not found to be affected by the administration of the ßi blocker, practolol [2]. It has been well documented that active labor reduces uteroplacental blood flow. Spontaneous äs well äs oxytocin-induced and prostaglandininduced uterine contractions decrease uterine blood flow in the sheep [11, 21] , the dog [4] , the monkey [23] and man [5] , It is suggested that the reduction takes place primarily in placental circulation äs myometrial flow is maintained [10] . In the present study, oxytocin-induced uterine contractions significantiy reduced uterine blood flow by a 25% average. Infusion of terbutaline (rate I and rate II) tended to increase uterine blood flow, but in the absence of uterine contractions, the over-all effects of terbutaline on the uterine circulation were not statistically significant. Similarly, fenoterol [10] and ritodrine [8] which increase cardiac Output, fail to influence uteroplacental blood flow in the pregnant ewe. The increase in uterine blood flow with terbutaline is likely to be caused by an attenuation of uterine contractions. On the other hand, terbutaline at a high infusion rate (rate III) tended to produce a fall in uterine blood flow both in oxytocin-induced labor and when there were no contractions. As no correlations were found between these changes in uterine blood flow and changes in systolic blood pressure (r = 0.204), diastolic blood pressure (r = 0.570), pulse pressure (r = 0.313) or uterine activity (r « 0.104), we feel that the reduction in blood flow is probably mediated by a direct pharmacological effect of terbutaline on the uterine vasculature. These conclusions were also recently hypothesized for ritodrine infusion in sheep [9] . Any increment in tocolytic efficacy could be offset by drastic reductions in theplacental blood supply. It ,ip noteworthy, on the other hand, that bolus injection of 250 % of terbutaline caused a 25% increase in uterine blood flow äs it also immediately suppressed all uterine contractions. The fetal condition remained unchanged.
The series of separate investigations making up this study indicate that terbutaline, administered to the pregnant ewe for short periods and at no greater rate than 0.2-0.4 g/min. 9 is a reliable and safe tocolytic agent which does not härm the fetus.
Maternal and fetal effects of the drug when administration is prolonged remain to be determined.
Summary
The effect of terbutaline on the immature fetus, äs well äs on the uterine activity and blood flow, were investigated before and during oxytocin-induced uterine contractions in ten pregnant ewes prepared for chronic studies. The drug was administered either into the maternal or the fetal circulation. Terbutaline was infusedinto the maternal femoral vein for 20 minutes at three sequential rates (0.2, 0.4 and 0.8 Mg/kg/min) in four experiments when uterine activity was absent, and in eight experiments in the presence of well-established uterine contractions. In addition, a bolus injection of the drug was given in eight separate experiments: four with oxytocin-induced contractions and four without. In seven experiments, terbutaline was infused directly into the fetal jugular vein. Maternal and fetal blood pressure, heart rates and intraamniotic pressure were monitored throughout the study. Arterial blood samples were withdrawn at intervals from ewe and fetus simultaneously to measure pH, PCOj and PO 2 . Intravenous infusion of terbutaline to the mother at rates of 0.2-0.8 Mk/kg/min increased maternal heart rate in all experiments and suppressed uterine contractions which had been induced by oxytocin. The changes were doserelated. Low dose terbutaline had little effect on maternal blood pressure or uterine blood flow, but at a high infusion rate the drug produced a fall in uterine blood flow both in oxytocin-induced labor and when there were no contractions. The reduction in uterine blood flow did not correlate with alterations in systolic or diastolic blood pressure, pulse pressure or uterine activity. The reduction in blood flow is therefore probably due to a direct effect of terbutaline on the uterine vasculature. Bolus injection of 250 Mg/terbu taline caused a 25% increase in uterine blood flow and also immediately suppressed all uterine contracions. Tolerance of the drug was limited only by a consistent increase in heart rate. When terbutalyne was infused directly into the immature fetus at rate of 0.4 to 0.8 Mg/k g/m in, fetal blood pressure and heart rate remained essentially unchanged. In order to produce significant increase in the fetal heart rate and fall ; in blood pressure, 4.0 to 10.0 Mg/kg/min was necessary. In contrast, the near term fetuses responded promptly to the drug, 0.4 Mg/kg/min producing tachycardia, büt not hypotension. Although other tocolytic agents such äs ritodrine, sulbutamol and diazoxide also cause fetal hypotension, tachycardia and acidosis, this study demonstrated that lowdose, short-term administration of terbutaline infused into the maternal circulation caused no significant changes in fetal blood pressure, heart rate or blood pH and gases, nor did bolus injection change the fetal condition. It was concluded that terbutaline is a reliable and safe tocolytic agent which, if infused at no greater rate than 0.2-0.4 Mg/ kg/min and foi short periods (20 minutes) does not cause adverse effects in the fetus. At a high dosage (0.8 Mg/kg/ min) there was a fall in uterine biood flow which appeär to be a direct effect on uterine vasculature. Maternal and fetal effects when administration is prolonged are still unknown.
Keywords: Beta mimetics, sheep fetus, terbutaline, tocolysis, toxicity. L'administration par infusion de terbutaline a la mere a des doses de 0.2 a 0.8 microg/kg/min augmente la frequence cardiaque maternelle dans tous les cas et supprime les contractions uterines induites par l'ocytocine. Les modiflcations correspondent aux doses appliquees. Une faible dose de terbutaline n'avait qu'un effet faible sur la tension arterielle maternelle ou sur le flux sanguin uterin, par contre une perfusion hautement concentree provoquait la chute du flux sanguin uterin aussi bien au cours du travail induit par l'ocytocine qu'en l'absence de contraction. La reduction de la perfusion uterine n'est pas en correlation avec les perturbations de la pression sanguine systolique ou diastolique, avec le pouls ou l'activite uterine. Ainsi la reduction de la perfusion uterine semblet-elle liee a un effet direct de la terbutaline sur la vasculaxisation uterine. Les injections isolees de 250microgde terbutaline entrainaient une augmentation du flux sanguin uterin de 25% et supprimaient en meine temps toute contraction uterine. La toierance du medicament n'affectait qu'une importante augmentation de la frequence cardiaque. Lorsque la terbutaline etait perfusee directement au foetus immature a raison de 0.4 ou 0.8 microg/kg/min, la frequence cardiaque et la tension arterielle foetales demeuraient pratiquement indiangees. Seules des applications de 4.0 a 10.0 microg/kg/min induisaient des augmentations significatives de la frequence cardiaque et des chutes de pression sanguine. Curieusement les foetus proches du terme accusaient une reaction plus rapide a la drogue, 0.4 microg/kg/min produisant une tachycaidie mais sans hypotension. Alors que les autres agents tocolytiques tels la ritodrine, le salbutamol et le diazoxide entrainent egalement une hypotension foetale, une tachycardie et de l'acidose, cette etude montre qu'une dose faible et une courte duree de perfusion maternelle de terbutaline n'entraine point de modifications significatives de la tension sanguine foetale, de la frequence cardiaque ou du pH et des gaz du sang, pas plus que l'injection unique ne change les conditions foetales.
On peut en conclure que la terbutaline est un agent tocolytique fiable et sur qui, a condition de ne point etie administre a des doses 'superieures a 0.2 ou 0.4 microg/kg/min pendant une periode breve (20 minutes), n'entraine point d'effets indesirables chez le foetus. Des doses excedant 0.8 microg/kg/min ü survient une chute du flux sanguin uterin qui semble etre lie a un effet direct sur lä vascularisation uterine. Les effets chez la mere et chez le foetus d'une administration prolongee ne sont encore point connus.
Mots-cles: Beta-mimetiques, foetus de mouton, terbutaline, tololyse, toxicite. 
